Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055

MERCK & CO., INC. (MRK)

115
Delayed Quote. Delayed Nyse - 07/22 04:00:11 pm
58.43 USD   +0.74%
1d ago EXCLUSIVE - INDIA'S LUPIN, U.S. FIRM : sources
1d ago India's Lupin, U.S. firms weigh bids for GSK's mature drugs -sources
1d ago RECKITT BENCKISER : Aurelius buying Scholl shoes
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Merck & Co., Inc. : Merck to Present at Deutsche Bank 37th Annual Health Care Conference

05/08/2012 | 08:15am US/Eastern
Recommend:
0

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter Kellogg, executive vice president and chief financial officer and Nancy Thornberry, senior vice president and franchise head for diabetes and endocrinology are scheduled to present at the Deutsche Bank 37th Annual Health Care Conference in Boston, Mass. on May 9 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Merck
Media:
Ron Rogers, (908) 423-6449
or
Investors:
Carol Ferguson, (908) 423-4465


© Business Wire 2012
Recommend :
0
React to this article
Latest news on MERCK & CO., INC.
1d ago EXCLUSIVE - INDIA'S LUPIN, U.S. FIRM : sources
1d ago India's Lupin, U.S. firms weigh bids for GSK's mature drugs -sources
1d ago RECKITT BENCKISER : Aurelius buying Scholl shoes
2d ago Aurelius buys Scholl shoe business from Reckitt Benckiser
7d ago MERCK : Study Results from Merck & Company Broaden Understanding of Herpes Zoste..
7d ago MERCK : New Findings from Merck & Company in the Area of Immunoglobulins Describ..
7d ago MERCK : Findings in the Area of Clostridium difficile Reported from Merck & Comp..
07/11 Mylan near multibillion-dollar deal for Abbott drug assets - sources
07/11 EXCLUSIVE : Mylan near multibillion-dollar deal for Abbott drug assets - sources
07/11 Private equity takes on Big Pharma's carve-out challenge
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
Merck _ Co., Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF